Release of autologous growth factors

Release of autologous growth factors refers to a therapeutic mechanism in regenerative medicine where endogenous signaling proteins are concentrated and delivered to injured tissues to promote healing. This process is not a single molecular target but rather a physiological cascade involving the degranulation of platelets or the activation of monocytes to release a variety of cytokines and growth factors, such as Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-beta), and Vascular Endothelial Growth Factor (VEGF) (StatPearls, 2023). These factors bind to their respective transmembrane receptors on target cells, such as fibroblasts and mesenchymal stem cells, to stimulate cell proliferation, chemotaxis, and angiogenesis (Frontiers in Bioengineering and Biotechnology, 2020). Clinically, this is most commonly achieved through Platelet-Rich Plasma (PRP) or Autologous Conditioned Serum (ACS) therapies, which are used to treat musculoskeletal disorders like osteoarthritis and chronic tendinopathies (Journal of Orthopaedic Surgery and Research, 2018). The therapeutic goal is to mimic and enhance the natural wound-healing environment by providing a high concentration of bioactive molecules directly to the site of pathology. However, the efficacy of this approach is often limited by the high degree of variability in growth factor concentrations between individual patients and the lack of standardized preparation methods.

Other names

Autologous growth factor therapyEndogenous growth factor releasePlatelet-derived growth factor releaseAutologous cytokine therapy

The mechanism involves the isolation and concentration of autologous blood components, followed by their activation (e.g., via calcium chloride or thrombin) to trigger the release of alpha-granule contents from platelets. These released growth factors then act as ligands for various tyrosine kinase receptors and other cell-surface receptors, initiating intracellular signaling pathways like MAPK/ERK and PI3K/Akt that drive tissue regeneration and inflammation modulation (StatPearls, 2023).